147 related articles for article (PubMed ID: 35460975)
21. Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors.
Reinbold R; Hvinden IC; Rabe P; Herold RA; Finch A; Wood J; Morgan M; Staudt M; Clifton IJ; Armstrong FA; McCullagh JSO; Redmond J; Bardella C; Abboud MI; Schofield CJ
Nat Commun; 2022 Aug; 13(1):4785. PubMed ID: 35970853
[TBL] [Abstract][Full Text] [Related]
22. Ivosidenib: First Global Approval.
Dhillon S
Drugs; 2018 Sep; 78(14):1509-1516. PubMed ID: 30209701
[TBL] [Abstract][Full Text] [Related]
23. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.
Lowery MA; Burris HA; Janku F; Shroff RT; Cleary JM; Azad NS; Goyal L; Maher EA; Gore L; Hollebecque A; Beeram M; Trent JC; Jiang L; Fan B; Aguado-Fraile E; Choe S; Wu B; Gliser C; Agresta SV; Pandya SS; Zhu AX; Abou-Alfa GK
Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):711-720. PubMed ID: 31300360
[TBL] [Abstract][Full Text] [Related]
24. Assessing acquired resistance to IDH1 inhibitor therapy by full-exon
Oltvai ZN; Harley SE; Koes D; Michel S; Warlick ED; Nelson AC; Yohe S; Mroz P
Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33832922
[TBL] [Abstract][Full Text] [Related]
25. Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.
Choe S; Wang H; DiNardo CD; Stein EM; de Botton S; Roboz GJ; Altman JK; Mims AS; Watts JM; Pollyea DA; Fathi AT; Tallman MS; Kantarjian HM; Stone RM; Quek L; Konteatis Z; Dang L; Nicolay B; Nejad P; Liu G; Zhang V; Liu H; Goldwasser M; Liu W; Marks K; Bowden C; Biller SA; Attar EC; Wu B
Blood Adv; 2020 May; 4(9):1894-1905. PubMed ID: 32380538
[TBL] [Abstract][Full Text] [Related]
26.
Megías-Vericat JE; Ballesta-López O; Barragán E; Montesinos P
Blood Lymphat Cancer; 2019; 9():19-32. PubMed ID: 31413655
[TBL] [Abstract][Full Text] [Related]
27. SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML.
DiNardo CD; Stein EM
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):769-772. PubMed ID: 30416011
[TBL] [Abstract][Full Text] [Related]
28. Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.
Chaturvedi A; Herbst L; Pusch S; Klett L; Goparaju R; Stichel D; Kaulfuss S; Panknin O; Zimmermann K; Toschi L; Neuhaus R; Haegebarth A; Rehwinkel H; Hess-Stumpp H; Bauser M; Bochtler T; Struys EA; Sharma A; Bakkali A; Geffers R; Araujo-Cruz MM; Thol F; Gabdoulline R; Ganser A; Ho AD; von Deimling A; Rippe K; Heuser M; Krämer A
Leukemia; 2017 Oct; 31(10):2020-2028. PubMed ID: 28232670
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence.
Stemer G; Rowe JM; Ofran Y
Blood Lymphat Cancer; 2021; 11():41-54. PubMed ID: 34188585
[TBL] [Abstract][Full Text] [Related]
30. What to use to treat AML: the role of emerging therapies.
Thol F
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):16-23. PubMed ID: 34889359
[TBL] [Abstract][Full Text] [Related]
31. Myelodysplastic Syndrome and Sweet's Syndrome Are Associated with a Mutation in Isocitrate Dehydrogenase 1.
Snyder R; Libby T; Raciti P; Amin B; Jacobson M; Rakheja D; Fleming K; Bartenstein M; Zhu C; Goel S; Verma AK; Shastri A
Anticancer Res; 2018 Apr; 38(4):2201-2205. PubMed ID: 29599340
[TBL] [Abstract][Full Text] [Related]
32. IDH1 inhibitor shows promising early results.
Cancer Discov; 2015 Jan; 5(1):4. PubMed ID: 25583779
[TBL] [Abstract][Full Text] [Related]
33. Ivosidenib Deemed Safe, Effective in AML.
Cancer Discov; 2018 Aug; 8(8):OF1. PubMed ID: 29934313
[TBL] [Abstract][Full Text] [Related]
34. [Clinical analysis of the combination regimen with Bcl-2 inhibitor venetoclax in the treatment of 30 cases of acute myeloid leukemia with IDH1/2 mutation].
Wang X; Bao XB; Zhang J; Song BQ; Li MY; Xie JD; Shen HJ; Wu DP; Qiu HY
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):691-694. PubMed ID: 36709157
[No Abstract] [Full Text] [Related]
35. Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation.
Fan B; Dai D; DiNardo CD; Stein E; de Botton S; Attar EC; Liu H; Liu G; Lemieux I; Agresta SV; Yang H
Cancer Chemother Pharmacol; 2020 May; 85(5):959-968. PubMed ID: 32296873
[TBL] [Abstract][Full Text] [Related]
36. Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia.
Boutzen H; Saland E; Larrue C; de Toni F; Gales L; Castelli FA; Cathebas M; Zaghdoudi S; Stuani L; Kaoma T; Riscal R; Yang G; Hirsch P; David M; De Mas-Mansat V; Delabesse E; Vallar L; Delhommeau F; Jouanin I; Ouerfelli O; Le Cam L; Linares LK; Junot C; Portais JC; Vergez F; Récher C; Sarry JE
J Exp Med; 2016 Apr; 213(4):483-97. PubMed ID: 26951332
[TBL] [Abstract][Full Text] [Related]
37. Sweet's syndrome associated with hematological malignancies.
Maller B; Bigness A; Moiño D; Greene J
Leuk Res; 2020 Dec; 99():106461. PubMed ID: 33099235
[TBL] [Abstract][Full Text] [Related]
38.
Srinivasan A; Zhou Y; Scordino T; Prabhu S; Wierenga A; Simon G; Wierenga KJ; Thompson J; Shah R; Sinha AA
Pediatr Hematol Oncol; 2020 Aug; 37(5):431-437. PubMed ID: 32166993
[TBL] [Abstract][Full Text] [Related]
39. Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications.
Lee S; Urman A; Desai P
Leuk Lymphoma; 2019 Nov; 60(11):2635-2645. PubMed ID: 30958073
[TBL] [Abstract][Full Text] [Related]
40. Ivosidenib and Azacitidine in IDH1-Mutated AML.
Goodman AM; Mohyuddin GR; Prasad V
N Engl J Med; 2022 Jun; 386(26):2536. PubMed ID: 35767449
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
